Telix Pharmaceuticals Statistics
Total Valuation
Telix Pharmaceuticals has a market cap or net worth of 4.26 billion. The enterprise value is 4.19 billion.
| Market Cap | 4.26B |
| Enterprise Value | 4.19B |
Important Dates
The next estimated earnings date is Wednesday, August 21, 2024.
| Earnings Date | Aug 21, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Telix Pharmaceuticals has 334.23 million shares outstanding. The number of shares has increased by 4.41% in one year.
| Shares Outstanding | 334.23M |
| Shares Change (YoY) | +4.41% |
| Shares Change (QoQ) | +2.44% |
| Owned by Insiders (%) | 41.49% |
| Owned by Institutions (%) | 12.56% |
| Float | 254.75M |
Valuation Ratios
The trailing PE ratio is 1,275.00 and the forward PE ratio is 21.55.
| PE Ratio | 1,275.00 |
| Forward PE | 21.55 |
| PS Ratio | 7.79 |
| Forward PS | n/a |
| PB Ratio | 35.20 |
| P/FCF Ratio | 468.26 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 61.31, with an EV/FCF ratio of 460.65.
| EV / Earnings | 190.40 |
| EV / Sales | 7.67 |
| EV / EBITDA | 61.31 |
| EV / EBIT | 67.98 |
| EV / FCF | 460.65 |
Financial Position
The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.11.
| Current Ratio | 1.63 |
| Quick Ratio | 1.37 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.19 |
| Debt / FCF | 1.40 |
| Interest Coverage | 21.46 |
Financial Efficiency
Return on equity (ROE) is 18.19% and return on invested capital (ROIC) is 36.72%.
| Return on Equity (ROE) | 18.19% |
| Return on Assets (ROA) | 7.66% |
| Return on Capital (ROIC) | 36.72% |
| Revenue Per Employee | 1.32M |
| Profits Per Employee | 53,054 |
| Employee Count | 415 |
| Asset Turnover | 2.17 |
| Inventory Turnover | 25.12 |
Taxes
In the past 12 months, Telix Pharmaceuticals has paid 5.02 million in taxes.
| Income Tax | 5.02M |
| Effective Tax Rate | 18.57% |
Stock Price Statistics
The stock price has increased by +62.95% in the last 52 weeks. The beta is 2.43, so Telix Pharmaceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 2.43 |
| 52-Week Price Change | +62.95% |
| 50-Day Moving Average | 10.70 |
| 200-Day Moving Average | 7.96 |
| Relative Strength Index (RSI) | 63.79 |
| Average Volume (20 Days) | 15,223 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Telix Pharmaceuticals had revenue of 546.86 million and earned 22.02 million in profits. Earnings per share was 0.07.
| Revenue | 546.86M |
| Gross Profit | 345.44M |
| Operating Income | 61.94M |
| Pretax Income | 24.27M |
| Net Income | 22.02M |
| EBITDA | 68.37M |
| EBIT | 61.67M |
| Earnings Per Share (EPS) | 0.07 |
Balance Sheet
The company has 81.99 million in cash and 12.75 million in debt, giving a net cash position of 69.24 million or 0.21 per share.
| Cash & Cash Equivalents | 81.99M |
| Total Debt | 12.75M |
| Net Cash | 69.24M |
| Net Cash Per Share | 0.21 |
| Equity (Book Value) | 121.06M |
| Book Value Per Share | 0.36 |
| Working Capital | 63.65M |
Cash Flow
In the last 12 months, operating cash flow was 23.17 million and capital expenditures -14.06 million, giving a free cash flow of 9.10 million.
| Operating Cash Flow | 23.17M |
| Capital Expenditures | -14.06M |
| Free Cash Flow | 9.10M |
| FCF Per Share | 0.03 |
Margins
Gross margin is 63.17%, with operating and profit margins of 11.33% and 4.03%.
| Gross Margin | 63.17% |
| Operating Margin | 11.33% |
| Pretax Margin | 4.44% |
| Profit Margin | 4.03% |
| EBITDA Margin | 12.50% |
| EBIT Margin | 11.28% |
| FCF Margin | 1.66% |
Dividends & Yields
Telix Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.41% |
| Shareholder Yield | -4.41% |
| Earnings Yield | 0.52% |
| FCF Yield | 0.21% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |